Literature DB >> 10802791

Quality of life measures in epilepsy: how well can they detect change over time?

G L Birbeck1, S Kim, R D Hays, B G Vickrey.   

Abstract

OBJECTIVE: To evaluate the ability of health-related quality of life (HRQOL) measures to detect change over time in persons with epilepsy.
BACKGROUND: The application of HRQOL measures in clinical trials has been limited by a dearth of information regarding their abilities to measure change over time (i.e., their responsiveness). To calculate responsiveness, one must categorize subjects as "changed" or "unchanged" by a priori criteria.
METHODS: The authors analyzed data collected at baseline and at 28-week follow-up from an antiepileptic drug trial. Two different criteria for classifying subjects as changed or unchanged-one based on seizure frequency (where changed = attainment of seizure freedom) and one based on self-reported overall condition (where changed = improvement in overall condition)-were used. We compared responsiveness indices for two generic (Short Form [SF]-36 and SF-12) and two epilepsy-targeted (Quality of Life in Epilepsy [QOLIE]-89 and QOLIE-31) HRQOL measures. Two scoring procedures for the SF-36, one based on classic test theory and the other on item response theory (IRT), were compared.
RESULTS: Effect sizes of the most responsive HRQOL measures were medium to large. The shorter epilepsy-targeted measure had similar responsiveness indices to those of the longer measure. Epilepsy-targeted measures were consistently more responsive than generic measures under the overall condition criterion, but for the seizure freedom criterion, IRT scoring of the SF-36 yielded responsiveness indices comparable to those of the epilepsy-targeted measures.
CONCLUSION: Epilepsy-targeted health-related quality of life measures may be preferable to generic ones in longitudinal studies. Selection of a shorter epilepsy-targeted measure does not compromise responsiveness. Item response theory scoring should be applied to epilepsy-targeted HRQOL measures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10802791     DOI: 10.1212/wnl.54.9.1822

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Measurement of quality of life in neurodegenerative disorders.

Authors:  M D Welsh
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

2.  Item response theory and health outcomes measurement in the 21st century.

Authors:  R D Hays; L S Morales; S P Reise
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

3.  Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sheri L Maddigan
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

4.  A comparison of Rasch with Likert scoring to discriminate between patients' evaluations of total hip replacement surgery.

Authors:  R Fitzpatrick; J M Norquist; C Jenkinson; B C Reeves; R W Morris; D W Murray; P J Gregg
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

5.  Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy.

Authors:  J T Langfitt; B G Vickrey; M P McDermott; S Messing; A T Berg; S S Spencer; M R Sperling; C W Bazil; S Shinnar
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 4.147

6.  Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease.

Authors:  Holger J Schünemann; Roger Goldstein; M Jeffery Mador; Douglas McKim; Elisabeth Stahl; Lauren E Griffith; Ahmed M Bayoumi; Peggy Austin; Gordon H Guyatt
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

7.  Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease.

Authors:  J Müller-Nordhorn; S Roll; S N Willich
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

8.  Clinically important change in quality of life in epilepsy.

Authors:  S Wiebe; S Matijevic; M Eliasziw; P A Derry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

9.  Patient-identified disease burden in facioscapulohumeral muscular dystrophy.

Authors:  Nicholas E Johnson; Christine Quinn; Eileen Eastwood; Rabi Tawil; Chad R Heatwole
Journal:  Muscle Nerve       Date:  2012-12       Impact factor: 3.217

10.  Association of demographic, clinical and treatment variables with quality of life of patients with epilepsy in Greece.

Authors:  Charitomeni Piperidou; Anna Karlovasitou; Nikolaos Triantafyllou; Evagelia Dimitrakoudi; Aikaterini Terzoudi; Eleni Mavraki; Grigorios Trypsianis; Konstantinos Vadikolias; Ioannis Heliopoulos; Dimitrios Vassilopoulos; Stavros Balogiannis
Journal:  Qual Life Res       Date:  2008-07-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.